Tenax Therapeutics, INC.: insider trades · United States · SEC (Form 4)

About Tenax Therapeutics, INC.

Tenax Therapeutics, Inc. is a U.S.-based biopharmaceutical development company listed on the Nasdaq under the ticker TENX. Its business is centered on discovering, developing, and ultimately commercializing cardiovascular and pulmonary therapies for diseases with significant unmet medical need. For French-speaking investors, Tenax should be viewed as a specialty biotech name rather than a mature pharmaceutical company: it is largely a clinical-stage story, with valuation driven primarily by trial execution, regulatory milestones, and funding capacity rather than current product revenue. The company has undergone a long corporate evolution. Tenax traces its origins back to 1967, when it was originally formed in New Jersey under a different corporate identity. Over time, it changed name and structure before adopting the Tenax Therapeutics name in 2014. This history matters because it shows that the company is not a traditional established pharma platform, but rather a business that has been reshaped around cardiopulmonary drug development. Today, the operational headquarters is in Chapel Hill, North Carolina, United States, and the company has indicated that much of its workforce operates remotely. Tenax’s core strategy is built around levosimendan-based programs. The company highlights an oral formulation intended to maintain therapeutic levosimendan levels over time, as well as an intravenous levosimendan program being studied in pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF. Historically, Tenax has also worked on a reformulated imatinib program for pulmonary arterial hypertension. Taken together, these assets position the company as a highly focused developer in severe cardiopulmonary diseases where treatment options remain limited and clinical differentiation can be meaningful. From a competitive standpoint, Tenax operates in a field dominated by large multinational drugmakers and by other specialty biotech companies focused on heart failure, pulmonary hypertension, and adjacent cardiology indications. Its competitive edge is therefore not scale, but rather scientific specialization, concentrated clinical expertise, and the potential to advance differentiated late-stage assets. Recent company communications show that management is prioritizing the LEVEL phase 3 program, with enrollment milestones and topline data expected in 2026, alongside the initiation of a second phase 3 study, LEVEL-2. In March 2026, Tenax reported that it had reached its target randomization of 230 patients in LEVEL, with topline results expected in the third quarter of 2026. Geographically, Tenax is primarily a United States company, and its clinical development activities are organized through investigator sites in the U.S. and, depending on the protocol, other regions. For investors, this remains a classic small-cap biotech profile: potentially high upside if clinical data are supportive, but also meaningful execution, financing, and binary-event risk. Given the company’s Nasdaq listing in the United States, insider Form 4 filings and capital-markets updates are especially relevant indicators to monitor.